Clinical Trials

National/International Multicenter Clinical Trials

Science 37 Screening Colonoscopy:

Title: REEMPT CRC: Prevention of Colorectal Cancer Through Multiomics Blood Testing

Sponsor: Freenome Holdings, Inc.

Start Date: Aug 2021 (tentative)

Status: Upcoming

Science 37 NASH:

Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of STUDY DRUG in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

Sponsor: Science 37

Start Date: TBD

Status: Upcoming

MET642: A Sustained FXR Agonist with Best-in-Class Potential for the Treatment of NASH:

Title: Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients with Nonalcoholic Steatohepatitis (NASH)

Sponsor: Metacrine, Inc

Start Date: Mar 2021

End Date: Dec 2021

Status: Enrollment closed

NASH PASS a national registry of NASH:

Title: NASH PASS: A population based epidemiological NAFLD/NASH registry and research project

Sponsor: ProSciento, Inc

Start Date: Sep 2021

End Date: Jul 2021

Status: Ended until 2022

Regeneron Liver Biopsy:

Title: A study to evaluate narrow gauge core needle biopsy samples for measuring gene expression in the liver in patients with nonalcoholic steatohepatitis

Sponsor: Regeneron Pharmaceuticals, Inc.

Start Date: December 2020

End Date: May 2021

Status: Closed

AstraZeneca GLP-1 agonist in treatment of NASH:

Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)

Sponsor: MedImmune Limited, a wholly owned subsidiary of AstraZeneca

Start Date: Feb 2020

End Date: March 2021

Status: Closed